about
Elimination and eradication of neglected tropical diseases with mass drug administrations: a survey of expertsAntibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster-randomized clinical trialThe fitness cost of antibiotic resistance in Streptococcus pneumoniae: insight from the fieldCommunity risk factors for ocular Chlamydia infection in Niger: pre-treatment results from a cluster-randomized trachoma trialThe easiest children to reach are most likely to be infected with ocular Chlamydia trachomatis in trachoma endemic areas of NigerShort-term Forecasting of the Prevalence of Trachoma: Expert Opinion, Statistical Regression, versus Transmission ModelsControl of Trachoma from Achham District, Nepal: A Cross-Sectional Study from the Nepal National Trachoma ProgramReduction and return of infectious trachoma in severely affected communities in Ethiopia.When can antibiotic treatments for trachoma be discontinued? Graduating communities in three African countriesImportance of coverage and endemicity on the return of infectious trachoma after a single mass antibiotic distributionVisual outcomes in treated bacterial keratitis: four years of prospective follow-upImpact of mass azithromycin distribution on malaria parasitemia during the low-transmission season in Niger: a cluster-randomized trial.Nasopharyngeal Pneumococcal Serotypes Before and After Mass Azithromycin Distributions for Trachoma.Clinical activity and polymerase chain reaction evidence of chlamydial infection after repeated mass antibiotic treatments for trachomaVisual recovery in treated bacterial keratitis.Challenges of ophthalmic care in the developing world.Importance of including borderline cases in trachoma grader certificationReliability of measurements performed by community-drawn anthropometrists from rural Ethiopia.Does mass azithromycin distribution impact child growth and nutrition in Niger? A cluster-randomized trial.Childhood mortality in a cohort treated with mass azithromycin for trachoma.Efficacy of latrine promotion on emergence of infection with ocular Chlamydia trachomatis after mass antibiotic treatment: a cluster-randomized trial.Adverse events after mass azithromycin treatments for trachoma in EthiopiaReliability of trachoma clinical grading--assessing grading of marginal cases.Latrine promotion for trachoma: assessment of mortality from a cluster-randomized trial in Ethiopia.How reliable are tests for trachoma?--a latent class approach.The distribution of ocular Chlamydia prevalence across Tanzanian communities where trachoma is decliningEvidence for clonal expansion after antibiotic selection pressure: pneumococcal multilocus sequence types before and after mass azithromycin treatments.Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma.Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributionsThe clinical differentiation of bacterial and fungal keratitis: a photographic survey.'If an Eye Is Washed Properly, It Means It Would See Clearly': A Mixed Methods Study of Face Washing Knowledge, Attitudes, and Behaviors in Rural Ethiopia.Short-term forecasting of the prevalence of clinical trachoma: utility of including delayed recovery and tests for infectionAssociation of conjunctival bacterial infection and female sex in cicatricial trachoma.The Effect of Mass Azithromycin Distribution on Childhood Mortality: Beliefs and Estimates of Efficacy.A cluster-randomized controlled trial evaluating the effects of mass azithromycin treatment on growth and nutrition in NigerInter-Rater Agreement between Trachoma Graders: Comparison of Grades Given in Field Conditions versus Grades from Photographic ReviewAdult mortality in a randomized trial of mass azithromycin for trachomaChanging Azole Resistance: A Secondary Analysis of the MUTT I Randomized Clinical Trial.Vision-Related Quality-of-Life Outcomes in the Mycotic Ulcer Treatment Trial I: A Randomized Clinical Trial.Risk factors for low vision related functioning in the Mycotic Ulcer Treatment Trial: a randomised trial comparing natamycin with voriconazole.
P50
Q21562239-F91D5086-F661-4AE4-8DC5-CB8FF304BE53Q28476520-7310D703-4458-46E0-8B40-8F37F674A5B3Q28478903-E20F3471-BED7-4181-B67B-FDF8C607FCE1Q28482497-9DCF5EC2-500C-4288-A481-D9F4CA3988D4Q28484940-486A4D8E-D1DB-4B4F-B5EA-10A61AC17DBEQ28547443-AEC1DD83-188F-47FC-B7BC-28AE81ABBCC5Q28550184-F13F2AC7-0044-4C1F-8140-872791F0EC55Q33405255-AA22E4DF-D9F6-4018-9BD1-B7C3E1C2E497Q33468389-C34F52C7-AB0D-400B-99A8-EEDFDAE8A79AQ33496749-CA7858EF-00C3-44B9-8AE7-5137E63F397AQ33567447-C21A821B-80CB-4DAF-882F-1788C911104BQ33588501-D3328FED-B283-45C5-A529-87166C3E7264Q33609239-4EB7DC2C-EAB8-48FD-9BE5-D0D123562DA9Q33693683-112C1793-2D28-4FE9-AF17-FBA0E7BFAFB7Q33717370-B8A856B8-C127-49C1-9B72-C13C856E435EQ33779376-979EA385-3588-4F1C-981E-A4C9C008E8E6Q34138525-C186C743-5670-4186-ADF0-835A09F97DC2Q34146015-14C87CAB-6F3D-4D4C-9ECE-12CE68347187Q34165923-5338AF80-D4DE-4C3B-B734-BE15D85A5AA3Q35019794-63C7B402-7A0B-4556-A22B-576BF007C0FFQ35116687-3711DAC5-4461-4A22-A33E-511ADC2213E1Q35131411-8132AEBF-6574-4458-B17F-3F3B5D47E3EBQ35160381-B9C32136-B4BB-4E9E-AB1C-6C8CDCAF0E11Q35186850-BDD972C4-1EE3-401D-92FF-92432F75DC30Q35221151-68C6D495-B8A5-49F6-8E47-CCF9A05970EAQ35223739-9380F8AF-75C5-4B80-9D9A-6FF5C8345606Q35558838-5C8F7059-747A-498E-818E-3EF7B416AF9EQ35632891-5321786A-E327-4F04-A2C6-6DF9A2F178AAQ35797198-90095765-84FD-49BD-A3B1-57290D9CF27AQ35929981-D870B666-F64D-486D-BAB3-CCDA2F773221Q36176201-C8F74437-551E-47F6-B070-EBA30ED537EAQ36202123-0189EF74-8F07-448F-9085-0D1C3E2DA159Q36206762-3D40F6CF-D641-453A-8325-91D70BE9EF22Q36436259-CFF6E5CB-4AF4-4025-942F-EA9DFD4D66D5Q36522988-CD5DC760-80C3-4FA2-B65C-F45929ED753DQ36715056-2D39CC29-1354-4F29-A2A6-863B023916D8Q37109315-4A007C78-4FBA-488A-BFC4-6D4B5893F80DQ37130051-4D89D409-CBCE-446D-8B16-6084A85CF207Q37130503-A9B47417-0F1D-45AE-A773-BECD5B9799E5Q37136368-ADE86721-18EF-4430-8010-1322BECD9A4F
P50
description
researcher ORCID ID = 0000-0002-7118-1457
@en
name
Jeremy D Keenan
@ast
Jeremy D Keenan
@en
Jeremy D Keenan
@nl
type
label
Jeremy D Keenan
@ast
Jeremy D Keenan
@en
Jeremy D Keenan
@nl
prefLabel
Jeremy D Keenan
@ast
Jeremy D Keenan
@en
Jeremy D Keenan
@nl
P31
P496
0000-0002-7118-1457